• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CRISPR J . A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance

tetano

Editor, Senior Moderator
CRISPR J


. 2022 Nov 11.
doi: 10.1089/crispr.2022.0048. Online ahead of print.
A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance


Maturada Patchsung[SUP] 1 [/SUP], Aimorn Homchan[SUP] 1 2 [/SUP], Kanokpol Aphicho[SUP] 1 [/SUP], Surased Suraritdechachai[SUP] 1 [/SUP], Thanyapat Wanitchanon[SUP] 1 3 [/SUP], Archiraya Pattama[SUP] 4 [/SUP], Khomkrit Sappakhaw[SUP] 1 [/SUP], Piyachat Meesawat[SUP] 1 [/SUP], Thanakrit Wongsatit[SUP] 1 [/SUP], Artittaya Athipanyasilp[SUP] 1 4 [/SUP], Krittapas Jantarug[SUP] 1 [/SUP], Niracha Athipanyasilp[SUP] 4 [/SUP], Juthamas Buahom[SUP] 4 [/SUP], Supapat Visanpattanasin[SUP] 2 [/SUP], Nootaree Niljianskul[SUP] 5 [/SUP], Pimchai Chaiyen[SUP] 1 [/SUP], Ruchanok Tinikul[SUP] 2 [/SUP], Nuanjun Wichukchinda[SUP] 3 [/SUP], Surakameth Mahasirimongkol[SUP] 3 [/SUP], Rujipas Sirijatuphat[SUP] 6 [/SUP], Nasikarn Angkasekwinai[SUP] 6 [/SUP], Michael A Crone[SUP] 7 8 9 [/SUP], Paul S Freemont[SUP] 7 8 9 [/SUP], Julia Joung[SUP] 10 11 12 13 14 [/SUP], Alim Ladha[SUP] 10 11 12 13 14 [/SUP], Omar Abudayyeh[SUP] 12 [/SUP], Jonathan Gootenberg[SUP] 12 [/SUP], Feng Zhang[SUP] 10 11 12 13 14 [/SUP], Claire Chewapreecha[SUP] 15 16 [/SUP], Sittinan Chanarat[SUP] 2 [/SUP], Navin Horthongkham[SUP] 4 [/SUP], Danaya Pakotiprapha[SUP] 2 [/SUP], Chayasith Uttamapinant[SUP] 1 [/SUP]



Affiliations

Abstract

Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection-such as multiplexed detection for viral variant surveillance-may limit their widespread adoption. Herein, we developed a robust multiplexed clustered regularly interspaced short palindromic repeats (CRISPR)-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)-including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)-all the while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool-CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance that can be locally manufactured-may enable sustainable use of CRISPR diagnostics technologies for COVID-19 and other diseases in POC settings.
 
Back
Top Bottom